Annovis Bio Inc. (ANVS): Price and Financial Metrics


Annovis Bio Inc. (ANVS): $18.80

0.33 (+1.79%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ANVS Stock Price Chart Interactive Chart >

Price chart for ANVS

ANVS Price/Volume Stats

Current price $18.80 52-week high $23.91
Prev. close $18.47 52-week low $8.39
Day low $18.35 Volume 66,400
Day high $19.30 Avg. volume 55,649
50-day MA $16.31 Dividend yield N/A
200-day MA $13.57 Market Cap 153.48M

Annovis Bio Inc. (ANVS) Company Bio


Annovis Bio, Inc. develops drugs for Alzheimer's and Parkinson's diseases and other neurodegenerative disorders. It offers posiphen compound for mild cognitive impairment and early stage Alzheimer's disease and bisnorcymserine compound that inhibits amyloid formation and prevents the progression of the Alzheimer's disease. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Berwyn, PA.


ANVS Latest News Stream


Event/Time News Detail
Loading, please wait...

ANVS Latest Social Stream


Loading social stream, please wait...

View Full ANVS Social Stream

Latest ANVS News From Around the Web

Below are the latest news stories about ANNOVIS BIO INC that investors may wish to consider to help them evaluate ANVS as an investment opportunity.

ANNOVIS BIO ANNOUNCES TWO PRESENTATIONS AT THE AD/PD™ 2023 INTERNATIONAL CONFERENCE ON ALZHEIMER'S AND PARKINSON'S DISEASES

Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced the Company will be making two presentations at the upcoming AD/PD™ 2023 International Conference on Alzheimer's and Parkinson's Disease, which is taking place from March 28 through April 1, 2023, in Gothenburg, Sweden.

Yahoo | March 22, 2023

COYA, Dr. Reddy's Sign Deal for Proposed Abatacept Biosimilar

COYA and Dr. Reddy's enter into a license agreement where the latter will source proposed biosimilar of abatacept biosimilar to Coya to develop and commercialize COYA 302.

Yahoo | March 21, 2023

Deciphera (DCPH) Gets Breakthrough Tag for Qinlock Expanded Use

The FDA grants breakthrough tag to Qinlock for treating second-line GIST patients with mutations in KIT Exon 11 and 17/18. Stock up on Tuesday in response.

Yahoo | March 15, 2023

Mirum's (MIRM) Livmarli Gets FDA Nod for Expanded Use, Stock Up

Mirum Pharmaceuticals (MIRM) announces FDA approval of Livmarli for infants 3 months and older. Stock up 6% in response to the news.

Yahoo | March 15, 2023

Seagen (SGEN) Set to be Acquired by Pfizer for $43 B, Stock Up

Seagen is set to be acquired by the large-cap pharma company, Pfizer, at a valuation of $43 billion. The stock is up about 15% in response to the news.

Yahoo | March 14, 2023

Read More 'ANVS' Stories Here

ANVS Price Returns

1-mo 20.05%
3-mo N/A
6-mo 45.17%
1-year 34.29%
3-year 417.91%
5-year N/A
YTD 39.99%
2022 -23.61%
2021 133.16%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8111 seconds.